Personalized Secukinumab Treatment in Patients with Plaque Psoriasis Using Model-Informed Precision Dosing

Personalized Secukinumab Treatment in Patients with Plaque Psoriasis Using Model-Informed Precision Dosing

<b>Background/Objectives:</b> Patient care and control of inflammatory disorders, such as psoriasis, can be improved by model-informed precision dosing (MIPD) techniques based on population pharmacokinetic/pharmacodynamic (PK/PD) models. Clinical dose selection decisions based on MIPD st...

Full description

Saved in:

Bibliographic Details
Main Authors:	Karine Rodriguez-Fernandez, Javier Zarzoso-Foj, Marina Saez-Bello, Almudena Mateu-Puchades, Antonio Martorell-Calatayud, Matilde Merino-Sanjuan, Elena Gras-Colomer, Monica Climente-Marti, Victor Mangas-Sanjuan
Format:	Article
Language:	English
Published:	MDPI AG 2024-12-01
Series:	Pharmaceutics
Subjects:	psoriasis secukinumab pharmacokinetic/pharmacodynamic
Online Access:	https://www.mdpi.com/1999-4923/16/12/1576
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy of Secukinumab in Management of Erythrodermic Psoriasis: A Study in Treatment-naïve Cases
by: Aradhana Rout, et al.
Published: (2025-07-01)

Secukinumab: In psoriasis and beyond
by: Aditya K. Bubna, et al.
Published: (2025-01-01)

Successful Treatment of Pediatric Generalized Pustular Psoriasis with Secukinumab
by: Yu K, et al.
Published: (2025-01-01)

Real-Life Data of Secukinumab in Patients with Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis: Patient Baseline Characteristics Data from the PROMPT Study
by: Ploysyne Rattanakaemakorn, et al.
Published: (2024-11-01)

Experience in using secukinumab in patients with axial psoriatic arthritis
by: E. E. Gubar, et al.
Published: (2020-11-01)

Experience of using secukinumab in the treatmentof patients with psoriasis
by: N. V. Zilberberg, et al.
Published: (2021-11-01)

Secukinumab treatment of IgA nephropathy manifested by psoriasis complicated with nephrotic syndrome： a case report
by: Xie Ting-ting, et al.
Published: (2025-03-01)

Efficacy and Safety of Adalimumab and Secukinumab in Erythrodermic Psoriasis: A Single Centre Retrospective Study
by: Yachen Wang, et al.
Published: (2025-07-01)

Successful Treatment with Secukinumab in a Psoriasis Patient on Hemodialysis
by: Xiao Y, et al.
Published: (2025-07-01)

Secukinumab in refractory non-infectious anterior uveitis
by: Otto M. Olivas-Vergara, et al.
Published: (2025-02-01)

Complete treatment experience on psoriasis patients with secukinumab in real practice in Krasnodar region
by: L. S. Kruglova, et al.
Published: (2021-06-01)

Secukinumab: A safe option to treat psoriasis and psoriatic arthritis in the presence of interstitial lung disease
by: Raja Natarajan
Published: (2019-01-01)

Secukinumab treatment of IgA nephropathy manifested by psoriasis complicated with nephrotic syndrome： a case report
by: Xie Ting-ting, et al.
Published: (2025-03-01)

Awareness of the Risk of Paradoxical Psoriasis in Patients with SAPHO Syndrome Undergoing Treatment with Secukinumab: A Case Series
by: Xu C, et al.
Published: (2025-03-01)

Secukinumab Treatment in Patients With Hidradenitis Suppurativa in Real-World Clinical Settings: A Multicenter Study
by: Ece Erbağcı, et al.
Published: (2025-01-01)

Case Report: Secukinumab for the treatment of severe psoriasis in a patient with hereditary hemochromatosis
by: Yingzhe Yu, et al.
Published: (2025-08-01)

Clinical efficacy of secukinumab in treating sleep disorders in psoriatic patients
by: ZHOU Cuimei, et al.
Published: (2025-07-01)

SUCCESSFUL USE OF AN INTERLEUKIN 17 INHIBITOR (SECUKINUMAB) IN THE TREATMENT OF ISOLATED DESTRUCTIVE ENTHESITIS IN PSORIATIC ARTHRITIS
by: E. E. Gubar, et al.
Published: (2018-11-01)

Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection
by: Matteo Megna, et al.
Published: (2022-07-01)

Description of the Clinical Case of Adalimumab and Secukinumab Therapy of a Patient with Psoriatic Arthritis
by: V. V. Didenko, et al.
Published: (2021-05-01)

Fractional Carbon Dioxide Laser Combined with Secukinumab in the Treatment of Refractory Psoriasis Lesions on the Lower Legs
by: Ye H, et al.
Published: (2024-12-01)

Secukinumab Persistence in Patients with Psoriatic Arthritis: An Adalimumab-Matched Retrospective Cohort Database Study (FLYWAY)
by: Hideto Kameda, et al.
Published: (2025-03-01)

Apremilast Coadministered with Secukinumab for Effective Treatment of Acrodermatitis Continua of Hallopeau: A Case Report
by: Yao XY, et al.
Published: (2025-05-01)

Real world efficacy safety and drug survival of secukinumab over 6 years at the largest biological center in Poland
by: Anna Felis-Giemza, et al.
Published: (2025-07-01)

Nonscrapable yeast: A case of chronic hyperplastic candidiasis following secukinumab therapy
by: Gabriela A. Duchesne, BS, et al.
Published: (2025-09-01)

Long-Term efficacy and safety analysis of secukinumab in the treatment of pediatric generalized pustular psoriasis: a real-world study
by: Lu Xing, et al.
Published: (2025-12-01)

A Matching-Adjusted Indirect Comparison of Guselkumab and Secukinumab in Patients with Psoriatic Arthritis Over 52 Weeks
by: Suzy van Sanden, et al.
Published: (2025-06-01)

Clinical features, treatment, and prognosis of secukinumab-induced inflammatory bowel disease
by: Ronghui Li, et al.
Published: (2025-01-01)

Effectiveness and safety of secukinumab in axial spondyloarthritis and psoriatic arthritis: A retrospective analysis of its real-world usage from India
by: Sham Santhanam, et al.
Published: (2020-01-01)

Secukinumab-induced Crohn’s disease in a psoriasis patient: a case report highlighting paradoxical reactions to IL-17 inhibition
by: Huiling Dai, et al.
Published: (2025-07-01)

Retention rate and predictor factors of drug discontinuation in axial spondyloarthritis: a focus on certolizumab and secukinumab
by: Ebru Atalar, et al.
Published: (2025-06-01)

Successful treatment of generalized pustular psoriasis during pregnancy with secukinumab in a patient hypersensitive to spesolimab: a case report
by: Shuang Zhang, et al.
Published: (2025-12-01)

Use of the interleukin-17A inhibitor secukinumab in psoriatic arthritis: a subanalysis of the Russian population in the international randomized clinical trials FUTURE 1 and FUTURE 2
by: T. V. Korotaeva, et al.
Published: (2017-04-01)

Superior effect of adalimumab versus secukinumab on ultrasound-confirmed synovitis in psoriatic arthritis: comprehensive evidence from musculoskeletal ultrasound and clinical assessments
by: Yiyi Wang, et al.
Published: (2024-12-01)

The safety and optimal dosage of an interleukin-17A inhibitor (secukinumab) in the treatment of psoriatic arthritis in a patient with concomitant hepatitis C virus infection
by: E. E. Gubar, et al.
Published: (2019-10-01)

Clinical Characteristics of CARD14-Associated Papulosquamous Eruption and Evaluation of Therapeutic Efficacy of Secukinumab
by: Zhao X, et al.
Published: (2025-05-01)

Treatment of Psoriasis with II-17 Inhibitors: Comparison of Long-Term Effectiveness and Drug Survival of Secukinumab vs Ixekizumab in Real-World Practice
by: Lam J, et al.
Published: (2025-03-01)

RESULTS OF EVALUATING THE EFFICACY OF SECUKINUMAB VERSUS ADALIMUMAB IN TREATING PSORIATIC ARTHRITIS BY USING THE MATCHING-ADJUSTED INDIRECT COMPARISON METHOD
by: T. V. Korotaeva
Published: (2016-12-01)

Evaluation of the health care budget impact of secukinumab treatment in patients with ankylosing spondylitis
by: S. K. Zyryanov, et al.
Published: (2017-04-01)

Disease-Modifying Treatment of Psoriasis in Children
by: Nikolay N. Murashkin, et al.
Published: (2024-11-01)